A Study of Enzalutamide in Men With Nonmetastatic Prostate Cancer That Came Back After Treatment
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT): NCT02319837
Protocol ID: MDV3100-13 (C3431004)
PrintDownloadOpen Plain Language Summary Result: Click here